Adherence to oral migraine-preventive medications among patients with chronic migraine

Zsolt Hepp, David William Dodick, Sepideh F. Varon, Patrick Gillard, Ryan N. Hansen, Emily B. Devine

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

Background: Chronic migraine (CM) is a disabling disorder characterized by ≥15 headache days per month that has been shown to significantly reduce quality of life. Migraine-prevention guidelines recommend preventive medications as the standard of care for patients with frequent migraine. The aim of this study was to assess adherence to 14 commonly prescribed oral migraine-preventive medications (OMPMs) among patients with CM. Methods: Retrospective claims analysis of a US claim database (Truven MarketScan® Databases) was queried to identify patients who were at least 18 years old, diagnosed with CM, and initiated an OMPM (antidepressants, beta blockers, or anticonvulsants) between January 1, 2008 and September 30, 2012. Medication possession ratios (MPR) and proportion of days covered (PDC) were calculated for each patient. A cutoff of ≥80% was used to classify adherence. The odds of adherence between OMPMs were compared using logistic regression models. Results: Of the 75,870 patients identified with CM, 8688 met the inclusion/exclusion criteria. Adherence ranged between 26% to 29% at six months and 17% to 20% at 12 months depending on the calculation used to classify adherence (PDC and MPR, respectively). Adherence among the 14 OMPMs was similar except for amitriptyline, nortriptyline, gabapentin, and divalproex, which had significantly lower odds of adherence when compared to topiramate. Conclusion: Adherence to OMPMs is low among the US CM population at six months and worsens by 12 months.

Original languageEnglish (US)
Pages (from-to)478-488
Number of pages11
JournalCephalalgia
Volume35
Issue number6
DOIs
StatePublished - May 10 2015

Fingerprint

Migraine Disorders
Logistic Models
Insurance Claim Review
Nortriptyline
Amitriptyline
Valproic Acid
Standard of Care
Anticonvulsants
Antidepressive Agents
Headache
Quality of Life
Databases
Guidelines

Keywords

  • Adherence
  • administration
  • databases
  • factual
  • medication
  • migraine disorders
  • oral
  • statistics

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Adherence to oral migraine-preventive medications among patients with chronic migraine. / Hepp, Zsolt; Dodick, David William; Varon, Sepideh F.; Gillard, Patrick; Hansen, Ryan N.; Devine, Emily B.

In: Cephalalgia, Vol. 35, No. 6, 10.05.2015, p. 478-488.

Research output: Contribution to journalArticle

Hepp, Zsolt ; Dodick, David William ; Varon, Sepideh F. ; Gillard, Patrick ; Hansen, Ryan N. ; Devine, Emily B. / Adherence to oral migraine-preventive medications among patients with chronic migraine. In: Cephalalgia. 2015 ; Vol. 35, No. 6. pp. 478-488.
@article{1223197f6d2e409aa05a4d1265a44b18,
title = "Adherence to oral migraine-preventive medications among patients with chronic migraine",
abstract = "Background: Chronic migraine (CM) is a disabling disorder characterized by ≥15 headache days per month that has been shown to significantly reduce quality of life. Migraine-prevention guidelines recommend preventive medications as the standard of care for patients with frequent migraine. The aim of this study was to assess adherence to 14 commonly prescribed oral migraine-preventive medications (OMPMs) among patients with CM. Methods: Retrospective claims analysis of a US claim database (Truven MarketScan{\circledR} Databases) was queried to identify patients who were at least 18 years old, diagnosed with CM, and initiated an OMPM (antidepressants, beta blockers, or anticonvulsants) between January 1, 2008 and September 30, 2012. Medication possession ratios (MPR) and proportion of days covered (PDC) were calculated for each patient. A cutoff of ≥80{\%} was used to classify adherence. The odds of adherence between OMPMs were compared using logistic regression models. Results: Of the 75,870 patients identified with CM, 8688 met the inclusion/exclusion criteria. Adherence ranged between 26{\%} to 29{\%} at six months and 17{\%} to 20{\%} at 12 months depending on the calculation used to classify adherence (PDC and MPR, respectively). Adherence among the 14 OMPMs was similar except for amitriptyline, nortriptyline, gabapentin, and divalproex, which had significantly lower odds of adherence when compared to topiramate. Conclusion: Adherence to OMPMs is low among the US CM population at six months and worsens by 12 months.",
keywords = "Adherence, administration, databases, factual, medication, migraine disorders, oral, statistics",
author = "Zsolt Hepp and Dodick, {David William} and Varon, {Sepideh F.} and Patrick Gillard and Hansen, {Ryan N.} and Devine, {Emily B.}",
year = "2015",
month = "5",
day = "10",
doi = "10.1177/0333102414547138",
language = "English (US)",
volume = "35",
pages = "478--488",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Adherence to oral migraine-preventive medications among patients with chronic migraine

AU - Hepp, Zsolt

AU - Dodick, David William

AU - Varon, Sepideh F.

AU - Gillard, Patrick

AU - Hansen, Ryan N.

AU - Devine, Emily B.

PY - 2015/5/10

Y1 - 2015/5/10

N2 - Background: Chronic migraine (CM) is a disabling disorder characterized by ≥15 headache days per month that has been shown to significantly reduce quality of life. Migraine-prevention guidelines recommend preventive medications as the standard of care for patients with frequent migraine. The aim of this study was to assess adherence to 14 commonly prescribed oral migraine-preventive medications (OMPMs) among patients with CM. Methods: Retrospective claims analysis of a US claim database (Truven MarketScan® Databases) was queried to identify patients who were at least 18 years old, diagnosed with CM, and initiated an OMPM (antidepressants, beta blockers, or anticonvulsants) between January 1, 2008 and September 30, 2012. Medication possession ratios (MPR) and proportion of days covered (PDC) were calculated for each patient. A cutoff of ≥80% was used to classify adherence. The odds of adherence between OMPMs were compared using logistic regression models. Results: Of the 75,870 patients identified with CM, 8688 met the inclusion/exclusion criteria. Adherence ranged between 26% to 29% at six months and 17% to 20% at 12 months depending on the calculation used to classify adherence (PDC and MPR, respectively). Adherence among the 14 OMPMs was similar except for amitriptyline, nortriptyline, gabapentin, and divalproex, which had significantly lower odds of adherence when compared to topiramate. Conclusion: Adherence to OMPMs is low among the US CM population at six months and worsens by 12 months.

AB - Background: Chronic migraine (CM) is a disabling disorder characterized by ≥15 headache days per month that has been shown to significantly reduce quality of life. Migraine-prevention guidelines recommend preventive medications as the standard of care for patients with frequent migraine. The aim of this study was to assess adherence to 14 commonly prescribed oral migraine-preventive medications (OMPMs) among patients with CM. Methods: Retrospective claims analysis of a US claim database (Truven MarketScan® Databases) was queried to identify patients who were at least 18 years old, diagnosed with CM, and initiated an OMPM (antidepressants, beta blockers, or anticonvulsants) between January 1, 2008 and September 30, 2012. Medication possession ratios (MPR) and proportion of days covered (PDC) were calculated for each patient. A cutoff of ≥80% was used to classify adherence. The odds of adherence between OMPMs were compared using logistic regression models. Results: Of the 75,870 patients identified with CM, 8688 met the inclusion/exclusion criteria. Adherence ranged between 26% to 29% at six months and 17% to 20% at 12 months depending on the calculation used to classify adherence (PDC and MPR, respectively). Adherence among the 14 OMPMs was similar except for amitriptyline, nortriptyline, gabapentin, and divalproex, which had significantly lower odds of adherence when compared to topiramate. Conclusion: Adherence to OMPMs is low among the US CM population at six months and worsens by 12 months.

KW - Adherence

KW - administration

KW - databases

KW - factual

KW - medication

KW - migraine disorders

KW - oral

KW - statistics

UR - http://www.scopus.com/inward/record.url?scp=84926452793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926452793&partnerID=8YFLogxK

U2 - 10.1177/0333102414547138

DO - 10.1177/0333102414547138

M3 - Article

C2 - 25164920

AN - SCOPUS:84926452793

VL - 35

SP - 478

EP - 488

JO - Cephalalgia

JF - Cephalalgia

SN - 0333-1024

IS - 6

ER -